Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CGEM

Cullinan Oncology Inc

Dec 01 • 04:00PM ET

8.66

Dollar change +0.47
Percentage change 5.74	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.73	Insider Own	36.54%	Shs Outstand	45.80M	Perf Week	-1.14%
Market Cap	370.47M	Forward P/E	-	EPS next Y	-4.11	Insider Trans	-0.09%	Shs Float	27.15M	Perf Month	-6.68%
Income	-156.14M	PEG	-	EPS next Q	-0.96	Inst Own	66.00%	Short Float / Ratio	7.94% / 13.34	Perf Quarter	-20.18%
Sales	0.00M	P/S	-	EPS this Y	-271.66%	Inst Trans	-1.57%	Short Interest	2.16M	Perf Half Y	-17.76%
Book/sh	10.96	P/B	0.79	EPS next Y	-0.60%	ROA	-28.08%	Target Price	24.60	Perf Year	-30.33%
Cash/sh	10.90	P/C	0.79	EPS next 5Y	-	ROE	-29.60%	52W Range	7.78 - 13.74	Perf YTD	-17.91%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-33.13%	52W High	-36.97%	Beta	0.09
Dividend %	-	Quick Ratio	20.33	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	11.28%	ATR	0.60
Employees	62	Current Ratio	20.33	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	46.67	Volatility	8.33% 7.03%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-68.61%	Profit Margin	-	Rel Volume	1.81	Prev Close	8.19
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 08 BMO	Payout	0.00%	Avg Volume	161.56K	Price	8.66
Recom	1.00	SMA20	-4.35%	SMA50	-3.49%	SMA200	-15.40%	Volume	291,614	Change	5.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Loading…
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire)
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
04:35PM	Loading…
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 11:18AM	Why Are Cullinan Oncology Shares Rising Today? (Benzinga) +23.12%
02:00AM	Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taihos Acquisition of Cullinan Pearl (GlobeNewswire)
May-08-22 09:23AM	Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth (Simply Wall St.)
May-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
Apr-27-22 10:00AM	Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-05-22 08:00AM	Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Apr-04-22 04:34PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.55%
Mar-29-22 07:54AM	Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting (Benzinga)
Mar-28-22 04:01PM	Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Mar-17-22 07:08AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
07:00AM	Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 (GlobeNewswire)
Mar-09-22 08:00AM	Cullinan Oncology to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +8.91%
Mar-08-22 05:30PM	Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 (GlobeNewswire)
Feb-28-22 08:00AM	Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors (GlobeNewswire)
Feb-12-22 06:50AM	Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year (Simply Wall St.)
Feb-07-22 06:30AM	Cullinan Oncology to Present at SVB Leerinks 11th Annual Global Healthcare Conference (GlobeNewswire) +6.52%
Jan-10-22 06:30AM	Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment (GlobeNewswire)
Jan-05-22 09:00AM	Cullinan Oncology to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -6.69%
Jan-04-22 07:34AM	Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA (MarketWatch)
07:00AM	FDA Grants Breakthrough Therapy Designation for Cullinan Oncologys CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-16-21 01:04PM	Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients (Benzinga)
06:30AM	Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Dec-13-21 07:00AM	Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Nov-22-21 12:37PM	Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference (GlobeNewswire)
Nov-14-21 07:04AM	Cullinan Oncology, Inc. (NASDAQ:CGEM) insiders snagged a deal: Up US$35k on a US$4.3m investment (Simply Wall St.)
Nov-09-21 06:45AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-29-21 11:47AM	Do Hedge Funds Love Cullinan Oncology, Inc. (CGEM)? (Insider Monkey)
Oct-18-21 07:00AM	Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer (GlobeNewswire) -15.52%
Sep-08-21 04:01PM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-21 06:44AM	We're Hopeful That Cullinan Oncology (NASDAQ:CGEM) Will Use Its Cash Wisely (Simply Wall St.)
Aug-10-21 06:30AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results (GlobeNewswire) +6.70%
Aug-05-21 04:05PM	Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference (GlobeNewswire) +13.58%
Jul-19-21 07:56PM	Is Cullinan Oncology, Inc. (CGEM) A Good Stock To Buy? (Insider Monkey)
Jun-29-21 08:00AM	Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors (GlobeNewswire)
Jun-07-21 10:57AM	Cullinan Gets FDA Investigational Clearance for Leukemia Drug (TheStreet.com)
09:26AM	Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data (Zacks)
08:30AM	Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML (GlobeNewswire)
Jun-04-21 11:53AM	Why Cullinan Oncology Stock Is Skyrocketing Today (Motley Fool) +11.26%
09:00AM	Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearls CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
May-21-21 08:00AM	Cullinan Oncology Announces Management Transition (GlobeNewswire) -10.59%
May-19-21 05:00PM	Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021 (GlobeNewswire)
May-14-21 06:30AM	Cullinan Oncology Reports First Quarter 2021 Financial Results (GlobeNewswire)
Apr-08-21 01:38AM	Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? (Simply Wall St.)
Apr-07-21 10:08AM	Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-21 06:15AM	Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-21 09:48AM	Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) +8.06%
Feb-22-21 07:30AM	Cullinan Management, Inc. Announces Business Update (GlobeNewswire)
Jan-12-21 09:43PM	Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.68%
Jan-08-21 12:13AM	Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION) (GlobeNewswire)
Jan-07-21 09:03PM	Cullinan Management Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AHMED NADIM	President and CEO	Jun 28	Sale	11.40	759	8,653	115,822	Jun 29 04:59 PM
Trigilio Jeffrey	Chief Financial Officer	Jun 20	Sale	12.94	399	5,163	85,823	Jun 21 04:17 PM
Jones Jeffrey Alan	Chief Medical Officer	Jun 20	Sale	12.94	387	5,008	58,437	Jun 21 04:17 PM
SUMER JACQUELYN L	Chief Legal Officer	Jun 20	Sale	12.94	291	3,766	45,823	Jun 21 04:17 PM
Michaelson Jennifer	Chief Development Officer	Jun 20	Sale	12.94	238	3,080	90,033	Jun 21 04:17 PM
Trigilio Jeffrey	Chief Financial Officer	Jun 12	Sale	13.11	319	4,182	86,222	Jun 14 04:35 PM
Michaelson Jennifer	Chief Development Officer	Jun 12	Sale	13.11	176	2,307	90,271	Jun 14 04:35 PM
Michaelson Jennifer	Chief Development Officer	Jun 07	Option Exercise	4.30	100	430	90,547	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 07	Sale	12.40	100	1,240	90,447	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 06	Option Exercise	4.30	11,900	51,170	102,347	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 06	Sale	12.31	11,900	146,489	90,447	Jun 08 05:10 PM
AHMED NADIM	President and CEO	May 23	Sale	9.15	707	6,469	116,581	May 24 04:36 PM
Trigilio Jeffrey	Chief Financial Officer	May 18	Sale	8.76	399	3,495	86,541	May 19 04:44 PM
Jones Jeffrey Alan	Chief Medical Officer	May 18	Sale	8.76	394	3,451	58,824	May 19 04:46 PM
SUMER JACQUELYN L	Chief Legal Officer	May 18	Sale	8.76	291	2,549	46,114	May 19 04:45 PM
Michaelson Jennifer	Chief Development Officer	May 18	Sale	8.76	239	2,094	90,447	May 19 04:51 PM
Trigilio Jeffrey	Chief Financial Officer	May 12	Sale	8.78	347	3,047	86,940	May 16 05:28 PM
Michaelson Jennifer	Chief Development Officer	May 12	Sale	8.78	193	1,695	90,686	May 16 05:36 PM
AHMED NADIM	President and CEO	Apr 25	Sale	10.59	716	7,582	117,288	Apr 26 04:23 PM
Trigilio Jeffrey	Chief Financial Officer	Apr 18	Sale	10.71	398	4,263	87,287	Apr 20 04:34 PM
Jones Jeffrey Alan	Chief Medical Officer	Apr 18	Sale	10.71	392	4,198	59,218	Apr 20 04:38 PM
SUMER JACQUELYN L	Chief Legal Officer	Apr 18	Sale	10.71	290	3,106	46,405	Apr 20 04:30 PM
Michaelson Jennifer	Chief Development Officer	Apr 18	Sale	10.71	238	2,549	90,879	Apr 20 04:32 PM
Trigilio Jeffrey	Chief Financial Officer	Apr 12	Sale	10.22	318	3,250	87,685	Apr 14 06:35 PM
Michaelson Jennifer	Chief Development Officer	Apr 12	Sale	10.22	176	1,799	91,117	Apr 14 06:23 PM
AHMED NADIM	President and CEO	Mar 23	Sale	10.51	706	7,420	118,004	Mar 27 04:05 PM
Trigilio Jeffrey	Chief Financial Officer	Mar 20	Sale	11.32	399	4,517	88,003	Mar 27 04:05 PM
Jones Jeffrey Alan	Chief Medical Officer	Mar 20	Sale	11.32	390	4,415	59,610	Mar 27 04:05 PM
SUMER JACQUELYN L	Chief Legal Officer	Mar 20	Sale	11.32	305	3,453	46,695	Mar 27 04:05 PM
Michaelson Jennifer	Chief Development Officer	Mar 20	Sale	11.32	238	2,694	91,293	Mar 27 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Oncology Inc

Upgrade your FINVIZ experience